title: Respirable bacteriophages for the treatment of bacterial lung infections.
abstract: This review article discusses the development of respiratory therapeutics containing bacteriophages indicated for lung infections, specifically those that have become increasingly difficult to treat because of antibiotic resistance. Recent achievements and remaining problems are presented for each step necessary to develop a bacteriophage-containing dosage form for respiratory drug delivery, including selection of appropriate bacteriophages for therapy, processing and purification of phage preparations, formulation into a stable, solid dosage form, and delivery device selection. Safety and efficacy studies in animals and human subjects are also reviewed.
authors.affiliation: 1 Department of Mechanical Engineering, University of Alberta , Edmonton, Alberta, T6G 2G8, Canada .
authors.forename: Susan
authors.initials: S
authors.lastname: Hoe
authors.forename: Diana D
authors.initials: DD
authors.lastname: Semler
authors.forename: Amanda D
authors.initials: AD
authors.lastname: Goudie
authors.forename: Karlene H
authors.initials: KH
authors.lastname: Lynch
authors.forename: Sadaf
authors.initials: S
authors.lastname: Matinkhoo
authors.forename: Warren H
authors.initials: WH
authors.lastname: Finlay
authors.forename: Jonathan J
authors.initials: JJ
authors.lastname: Dennis
authors.forename: Reinhard
authors.initials: R
authors.lastname: Vehring
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000382:microbiology / Q000628:therapy*; D001435:Bacteriophages / Q000472:pathogenicity; D001691:Biological Therapy / Q000379:methods*; D024881:Drug Resistance, Bacterial; D006801:Humans; D008168:Lung / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000382:microbiology / Q000628:therapy*; D014774:Virulence
chemical_list: D000900:Anti-Bacterial Agents